TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11804247

Group type: EXPERIMENTAL
Intervention: Trihydroxyethylrutosides (HR) 300 mg, 2 tablets daily for 2 weeks
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Trihydroxyethylrutosides (HR) 300 mg, continued for another 2 weeks if symptoms persisted
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 9893776

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 8164116

Group type: COMPARATOR
Intervention: Water irrigation (Group B)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Zinc sulfate irrigation (Group C)
Number of subjects: 155
Study: 2820619

Group type: EXPERIMENTAL
Intervention: Cyclic combination of 2 mg oestradiol valerate (21 d) and 1 mg cyproterone acetate (11 d)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 29540584

Group type: EXPERIMENTAL
Intervention: CBD 5 mg/kg/d
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CBD 10 mg/kg/d
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CBD 20 mg/kg/d
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 26750743

Group type: EXPERIMENTAL
Intervention: Telephone-based self-management support intervention delivered by lay health educators
Number of subjects: 443
Study: 25280823

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT), 8 sessions
Number of subjects: 61

Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (E-TAU)
Number of subjects: 61
Study: 22035956

Group type: EXPERIMENTAL
Intervention: Nutritional counseling during 10 contacts
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements as needed until three months after hip fracture surgery
Number of subjects: 66
Study: 20142336

Group type: EXPERIMENTAL
Intervention: 2-injection technique (group 1, n = 56)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 4-injection technique (group 2, n = 58)
Number of subjects: 120
Study: 17432681

Group type: EXPERIMENTAL
Intervention: Xuezhikang (XZK) plus standard CHF treatment (angiotensin converting enzyme inhibitor, beta‐receptor inhibitor, digoxin, diuretic) for six months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard CHF treatment (angiotensin converting enzyme inhibitor, beta‐receptor inhibitor, digoxin, diuretic)
Number of subjects: 68
Study: 16234567

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: PIAF (Cisplatin, interferon alpha-2b, doxorubicin, fluorouracil)
Number of subjects: 188
Study: 11864671

Group type: EXPERIMENTAL
Intervention: 400 microg oral misoprostol
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 7743295

Group type: EXPERIMENTAL
Intervention: Curosurf (200 mg/kg initial dose; up to two additional doses of 100 mg/kg after 12 and 24 hours if needed)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Survanta (100 mg/kg initial dose; up to three additional doses of 100 mg/kg between six and 48 hours if needed)
Number of subjects: 75
Study: 2195163

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 352191

Group type: EXPERIMENTAL
Intervention: 1% etidocaine
Number of subjects: 41

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 41
Study: 29804498

Group type: EXPERIMENTAL
Intervention: Nonoffending mother scenario
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Nonoffending father scenario
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Thematic analysis of fault attributions
Number of subjects: 154
Study: 31869226

Group type: EXPERIMENTAL
Intervention: XGBoost model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consensus model from the top three models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Descriptor-based consensus model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local models for different ionization states
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Matched molecular pair (MMP) analysis
Number of subjects: 0
Study: 30669986

Group type: EXPERIMENTAL
Intervention: iSTEP mobile health intervention including Fitbit and text messages
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Barriers to healthy diet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Facilitators for healthy diet
Number of subjects: 20
Study: 28842733

Group type: COMPARATOR
Intervention: Low-dose KHCO3 (1 mmol/kg/day)
Number of subjects: 233

Group type: COMPARATOR
Intervention: High-dose KHCO3 (1.5 mmol/kg/day)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study: 27936845

Group type: EXPERIMENTAL
Intervention: Ongoing task with PM intention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ongoing task alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing task with PM execution rewarded
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing task with minimized PM demands
Number of subjects: 0
Study: 24086581

Group type: EXPERIMENTAL
Intervention: Therapeutic education on antibiotic use delivered by a pharmacist (30-minute face-to-face session).
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Therapeutic education on antibiotic use (intervention group).
Number of subjects: 300

Group type: COMPARATOR
Intervention: Fever control (control group).
Number of subjects: 300
Study: 21846460

Group type: EXPERIMENTAL
Intervention: FRP combined with metronidazole and amoxicillin
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: FRP combined with doxycycline
Number of subjects: 38

Group type: COMPARATOR
Intervention: FRP alone
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Systemic use of metronidazole and amoxicillin or doxycycline
Number of subjects: 38
Study: 19125434

Group type: EXPERIMENTAL
Intervention: Probiotic treatment in severe pancreatitis
Number of subjects: 731
Study: 17596104

Group type: EXPERIMENTAL
Intervention: Bevirimat (25 mg, 50 mg, 75 mg with 150 mg loading dose, 100 mg, 150 mg, 200 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 15238970

Group type: EXPERIMENTAL
Intervention: Visits to a dental health educator over a 2-year period
Number of subjects: 271
Study: 12964231

Group type: EXPERIMENTAL
Intervention: Emla (lignocaine/prilocaine) anaesthetic cream
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 9807138

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 7509495

Group type: EXPERIMENTAL
Intervention: 4 mg risperidone
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 8 mg risperidone
Number of subjects: 59

Group type: COMPARATOR
Intervention: 400 mg clozapine
Number of subjects: 59
Study: 2675953

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 60 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2027

Group type: EXPERIMENTAL
Intervention: Practolol (beta-adrenergic blockade)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Halothane anaesthesia
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no beta-adrenergic blockade)
Number of subjects: 21
Study: 31568286

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (5 U)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Saline injections (control)
Number of subjects: 43
Study: 28368334

Group type: EXPERIMENTAL
Intervention: High protein and fiber (HPHF; HP = 25 g, HF = 8 g)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Normal protein and high fiber (NPHF; NP = 12.5 g, HF = 8 g)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High protein and normal fiber (HPNF; HP = 25 g, NF = 2 g)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Normal protein and fiber (NPNF; NP = 12.5 g, NF = 2 g)
Number of subjects: 20
Study: 25752778

Group type: EXPERIMENTAL
Intervention: Aerobic training (AT, n=40)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Resistance training (RT, n=55)
Number of subjects: 95
Study: 23327614

Group type: EXPERIMENTAL
Intervention: Acetate containing dialysate (A(+)D)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Acetate free citrate containing dialysate (A(-)D)
Number of subjects: 29
Study: 21289497

Group type: EXPERIMENTAL
Intervention: Parent book reading intervention in the NICU
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (historical control)
Number of subjects: 116
Study: 20137328

Group type: EXPERIMENTAL
Intervention: Valsartan and Felodipine together in the morning (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Valsartan in the morning and Felodipine in the evening (Group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Felodipine in the morning and Valsartan in the evening (Group C)
Number of subjects: 90
Study: 16446323

Group type: EXPERIMENTAL
Intervention: BAY 43‐9006 (sorafenib) 400 mg orally twice daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BAY 43‐9006 (sorafenib)
Number of subjects: 20
Study: 15542012

Group type: EXPERIMENTAL
Intervention: Auditory metronome pacing
Number of subjects: 12

Group type: COMPARATOR
Intervention: Unassisted walking
Number of subjects: 12
Study: 11376545

Group type: EXPERIMENTAL
Intervention: WAND local anesthetic delivery system
Number of subjects: 20
Study: 9245041

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) at doses of 0.015, 0.25, 1.0, 2.0 micrograms/kg/min for 20 min each
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7994792

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of Adriamycin (ADM) plus verapamil (VR) (30 mg/24 ml physiological saline + 15 mg/6 ml saline)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Intravesical instillation of Adriamycin (ADM) alone (30 mg/30 ml physiological saline)
Number of subjects: 226
Study: 2838926

Group type: EXPERIMENTAL
Intervention: 5000 IU conventional heparin
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 5000 anti‐Xa U of low molecular weight heparin (Fragmin)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 9
Study: 31863121

Group type: EXPERIMENTAL
Intervention: Remote streaming support (RESS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional local support (LOS)
Number of subjects: 36
Study: 31563369

Group type: EXPERIMENTAL
Intervention: smooth surface roller
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: multilevel surface roller
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: GRID surface roller
Number of subjects: 36
Study: 28315878

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (no dexamethasone)
Number of subjects: 27
Study: 26165736

Group type: EXPERIMENTAL
Intervention: Intravenous proton pump inhibitor (PPI) before ESD
Number of subjects: 156

Group type: COMPARATOR
Intervention: No intravenous proton pump inhibitor (PPI) before ESD
Number of subjects: 156
Study: 23266658

Group type: EXPERIMENTAL
Intervention: Mindfulness induction (11 minutes)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Worry induction (11 minutes)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Baseline (8 minutes)
Number of subjects: 37
Study: 21943845

Group type: EXPERIMENTAL
Intervention: Early antiretroviral treatment (ART) initiated before 12 weeks
Number of subjects: 369

Group type: COMPARATOR
Intervention: Deferred ART initiated after immunological or clinical progression
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Early ART for infants with CD4 count <25%
Number of subjects: 369
Study: 18289229

Group type: EXPERIMENTAL
Intervention: Lidocaine-bicarbonate-adrenaline (1.8%, 0.76%, 1:200,000)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Levobupivacaine (0.5%)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lidocaine-bicarbonate-adrenaline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Levobupivacaine
Number of subjects: 40
Study: 16483383

Group type: EXPERIMENTAL
Intervention: Community and primary care interventions
Number of subjects: 10144
Study: 14708412

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: dexamethasone 8 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: saline
Number of subjects: 60
Study: 11024378

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (AR)
Number of subjects: 104

Group type: COMPARATOR
Intervention: No adjuvant treatment (Control)
Number of subjects: 104
Study: 9583652

Group type: EXPERIMENTAL
Intervention: Smoke-free worksite
Number of subjects: 8271
Study: 8147235

Group type: EXPERIMENTAL
Intervention: GTD/EE
Number of subjects: 189

Group type: COMPARATOR
Intervention: NGS/EE
Number of subjects: 189
Study: 3310563

Group type: EXPERIMENTAL
Intervention: Maximum activity of serum heat-stable lactate dehydrogenase (LD), analyzed every 12 hours for 48 to 108 hours
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Maximum activity of aspartate aminotransferase (ASAT), analyzed once daily for 3 days
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Maximum activity of creatine kinase (CK) and CK subunit B, analyzed every 6 hours for 48 hours
Number of subjects: 727
Study: 31954063

Group type: EXPERIMENTAL
Intervention: Oral stimulation
Number of subjects: 211

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 211
Study: 30518470

Group type: EXPERIMENTAL
Intervention: Counseling by nurses over the telephone
Number of subjects: 261

Group type: COMPARATOR
Intervention: Standard invitation to screening colonoscopy
Number of subjects: 261
Study: 26846612

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy-based psychoeducation
Number of subjects: 182

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 182
Study: 25902813

Group type: EXPERIMENTAL
Intervention: Early strategy: RRT initiated immediately
Number of subjects: 620

Group type: COMPARATOR
Intervention: Delayed strategy: RRT initiated based on severity criteria
Number of subjects: 620
Study: 23909846

Group type: EXPERIMENTAL
Intervention: Topical indometacin applied immediately post-PDT
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Intradermal injection of l-NAME into 5-ALA-PDT-treated sites
Number of subjects: 35

Group type: COMPARATOR
Intervention: 5-ALA-PDT
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Dermal microdialysate sampling
Number of subjects: 35
Study: 21568645

Group type: EXPERIMENTAL
Intervention: Paste containing fluoride
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Paste containing ACP
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Paste containing both fluoride and ACP
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no active ingredients)
Number of subjects: 40
Study: 18156521

Group type: EXPERIMENTAL
Intervention: Participants who read and signed the consent form accompanied by a family member/friend (intervention group, n = 70)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Participants who read and signed the consent form unaccompanied (control group, n = 73)
Number of subjects: 143
Study: 16552410

Group type: EXPERIMENTAL
Intervention: Dietary supplement with 40 mg/day ephedra alkaloids and 100 mg/day caffeine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control supplement
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Dietary supplement with ephedra and caffeine
Number of subjects: 61
Study: 14559886

Group type: EXPERIMENTAL
Intervention: Aprepitant regimen (aprepitant plus ondansetron and dexamethasone on day 1; aprepitant and dexamethasone on days 2 to 3; dexamethasone on day 4)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Standard therapy (ondansetron and dexamethasone on day 1; dexamethasone on days 2 to 4)
Number of subjects: 520
Study: 11106521

Group type: EXPERIMENTAL
Intervention: Forearm tourniquet
Number of subjects: 100

Group type: COMPARATOR
Intervention: Upper arm tourniquet
Number of subjects: 100
Study: 8668804

Group type: EXPERIMENTAL
Intervention: Gd-BOPTA-enhanced GRE T1-weighted MR imaging (0.10 mmol/kg) at 90 minutes
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Gd-BOPTA-enhanced SE T1-weighted MR imaging (0.05 and 0.10 mmol/kg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Gd-BOPTA-enhanced SE and GRE T1-weighted MR imaging (0.05 and 0.10 mmol/kg)
Number of subjects: 34
Study: 1421625

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg b.i.d. for 10 days)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Fleroxacin (400 mg s.i.d. for 7 days)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Fleroxacin (600 mg s.i.d. for 7 days)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Doxycycline (100 mg b.i.d. for 7 days)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg single dose)
Number of subjects: 322
Study: 6496357

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 53

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 53
Study: 30315506

Group type: EXPERIMENTAL
Intervention: Ambu® Aura Gain™
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ambu® Aura Once™
Number of subjects: 50
Study: 30089602

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg oral daily plus 500 mg intramuscular fulvestrant on day 1, 15, 29 and every 28 days thereafter
Number of subjects: 106

Group type: COMPARATOR
Intervention: Erlotinib alone 150 mg oral daily
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Combined therapy (fulvestrant + erlotinib) in EGFR wild type patients
Number of subjects: 106

Group type: COMPARATOR
Intervention: Erlotinib alone in EGFR wild type patients
Number of subjects: 106
Study: 26727076

Group type: EXPERIMENTAL
Intervention: NNC0195‐0092 (0.02, 0.04, 0.08, and 0.12 mg/kg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: NNC0195‐0092 (0.12 mg/kg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: NNC0195‐0092
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: NNC0195‐0092 (0.02 mg/kg and 0.04 mg/kg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Norditropin NordiFlex
Number of subjects: 34
Study: 24535604

Group type: EXPERIMENTAL
Intervention: SPI-guided analgesia (sufentanil bolus 10 μg when SPI > 50)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard practice (sufentanil administered according to standard clinical practice)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: SPI-guided analgesia
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 94
Study: 22798536

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 10,333 IU weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20109743

Group type: EXPERIMENTAL
Intervention: SQ-standardized grass allergy immunotherapy tablet Grazax (Phleum pratense 75,000 SQ-T/2,800 BAU)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study: 18030118

Group type: COMPARATOR
Intervention: Medpor
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Medpor-Plus
Number of subjects: 10
Study: 16124270

Group type: EXPERIMENTAL
Intervention: Inducer size and distance
Number of subjects: 0
Study: 12376782

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 50
Study: 10426855

Group type: EXPERIMENTAL
Intervention: Coronary Angioplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass Grafting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postrandomization events
Number of subjects: 0
Study: 7750333

Group type: EXPERIMENTAL
Intervention: Active B2 (salbutamol, 200 micrograms)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo B2
Number of subjects: 16
Study: 2405043

Group type: EXPERIMENTAL
Intervention: Oral physostigmine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Number of subjects: 20
Study: 7016447

Group type: EXPERIMENTAL
Intervention: Fenoterol (2 puffs, equivalent to 1.0 mumol free base)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Salbutamol (4 puffs, equivalent to 1.6 mumol free base)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30605991

Group type: EXPERIMENTAL
Intervention: SPI group (Surgical Pleth Index guided analgesia)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (Conventional analgesia technique)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study: 28352099

Group type: EXPERIMENTAL
Intervention: Soap-and-water handwashing
Number of subjects: 31

Group type: COMPARATOR
Intervention: Water-only handwashing
Number of subjects: 31
Study: 25955760

Group type: EXPERIMENTAL
Intervention: High-Fidelity Simulation (HFS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Frontal lessons only (Control)
Number of subjects: 0
Study: 24160483

Group type: EXPERIMENTAL
Intervention: Monthly reminders for sit-to-stand activity
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reminders implemented every 3 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low intensity, paper-based reminders
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High intensity reminders provided by a health care aide peer
Number of subjects: 24
Study: 21285288

Group type: EXPERIMENTAL
Intervention: Dynamic ankle-foot orthosis
Number of subjects: 28

Group type: COMPARATOR
Intervention: Tennis shoes (Control)
Number of subjects: 28
Study: 19596505

Group type: EXPERIMENTAL
Intervention: Trident Xtra Care
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Orbit Professional
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Orbit
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Extra
Number of subjects: 10
Study: 27770145

Group type: EXPERIMENTAL
Intervention: 186Re-HEDP administered at levels above 3.5 GBq
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Patient mean absorbed dose
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Whole-body absorbed dose
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Disease volume as measured from SPECT imaging
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Disease volume in multivariable analysis
Number of subjects: 57
Study: 16287345

Group type: EXPERIMENTAL
Intervention: Training group (n = 36)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nonexercise control group (n = 9)
Number of subjects: 45